<DOC>
	<DOCNO>NCT00549861</DOCNO>
	<brief_summary>Different study show fibrosis heart increase risk sudden death e.g . arrhythmia . Magnetic Resonance Imaging ( CMR ) easily identify even small area fibrosis heart muscle contrast agent application ( Gadolinium ) . With development faster scanner new contrast agent , detection small fibrotic area may even improve . In study , apply dedicate T1- T2-weighted CMR sequence administration Gadolinium-based contrast ( Gadobutrol , Gadovist ( r ) ) , study parameter full cardiac function , area edema , area inflammation area fibrosis . We hypothesize , detect fibrotic area myocardium use Gadobutrol ( Gadovist ( r ) ) good commonly use Gadolinium-DTPA contrast agent . We also hypothesize , fibrosis myocardium correlate prognosis patient .</brief_summary>
	<brief_title>Characterization Irreversible Myocardial Injury Cardiomyopathies Contrast-enhanced CMR</brief_title>
	<detailed_description>Dilated form cardiomyopathy present leave ventricular enlargement reduce ejection fraction . Myocardial fibrosis assess gradient echo sequence contrast application ( `` late enhancement '' ) proven outstanding value detection small irreversibly injured lesion use accurately characterize scarred tissue infarct ( Kim et al , Circulation 1999 ) , myocarditis ( Mahrholdt et al. , Circulation 2004 ) , hypertrophic cardiomyopathy ( Moon et al. , J Am Coll Cardiol 2004 ) . Whereas fibrosis pattern describe non-ischemic cardiomyopathy ( Mahrholdt et al. , Eur Heart J 2005 ) , little know specific regional distribution fibrous tissue within group dilate form . McCrohon et al . describe mid-mural patchy pattern patient global LV dysfunction evidence relevant coronary artery disease ( McCrohon et al. , Circulation 2003 ) . This study however , include right ventricular cardiomyopathy patient patient isolated non-compaction two important dilate form cardiomyopathy . Justification/relevance/purpose The presence fibrosis dilate form cardiomyopathy may predictive progression leave ventricular dysfunction time , may represent irreversible damage . Gadobutrol use contrast agent study ; significantly high relaxivity compare contrast agent potentially allow visualization small , focal area irreversible injury myocardium , thus increase sensitivity method identify even localize fibrotic area . Objective , hypothesis We attempt define disease-specific pattern extent spatial distribution irreversible tissue injury within group dilate form cardiomyopathy . We hypothesize patient dilate cardiomyopathy certain pattern late enhancement identify , useful specific phenotyping . We also hypothesize use Gadobutrol ( Gadovist® ) contrast agent identifies small area irreversible tissue injury well standard contrast agent may beneficial diagnose small fibrotic change .</detailed_description>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Cardiomyopathy , Dilated</mesh_term>
	<criteria>Known cardiomyopathy ( DCM , HCM , ARVC LVNC ) Clinical indication contrastenhanced Cardiac Magnetic Resonance study Ability give inform consent Any contraindication Magnetic Resonance Study include implanted device , claustrophobia etc . Allergic reaction Gadoliniumbased contrast agent Known adverse reaction Gadovist® Inability give informed consent Known longQT syndrome know conduction abnormality Pregnancy breastfeed Any exclusion criterion administration Gadovist® state product monograph Warning Precautions , e.g . Hx allergic disposition , bronchial asthma ; sickle cell anemia hemoglobinopathy ; renal insufficiency , hypokalemia ; convulsive state Conditions concomitant medication may prolong QTc interval , e.g . longQT syndrome , patient hypokalemia , receive Class I1 ( e.g . quinidine , procainamide ) class III ( amiodarone , sotalol ) know antiarrhythmogenic drug , medication know prolong QT interval ( cisapride , erythromycin , antipsychotic antidepressant ) since lack clinical experience potential risk concomitant use medication MRI contrast Patients severe renal impairment ( GFR &lt; 30mL/min ) Patients previous reaction MRI / CT contrast medium Patients acute renal dysfunction due hepatorenal syndrome patient perioperative liver transplantation period Patients endstage renal disease ( GFR &lt; 15mL/min/1.73m2 ) Unstable patient , e.g . CCU / ICU</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Cardiac Magnetic Resonance Imaging</keyword>
	<keyword>Contrast agent</keyword>
	<keyword>Gadobutrol</keyword>
	<keyword>Fibrosis</keyword>
	<keyword>Prognosis</keyword>
	<keyword>Magnetic Resonance</keyword>
	<keyword>Gadolinium</keyword>
</DOC>